Abstract
Schizophrenia (SZ) is a devastating complex genetic mental condition that is heterogeneous in terms of clinical etiologies, symptoms, and outcomes. Despite decades of postmortem, neuroimaging, pharmacological, and genetic studies of patients, in addition to animal models, much of the biological mechanisms that underlie the pathology of SZ remain unknown. The ability to reprogram adult somatic cells into human induced pluripotent stem cells (hiPSCs) provides a new tool that supplies live human neurons for modeling complex genetic conditions such as SZ. The purpose of this review is to discuss the technical and clinical constraints currently limiting hiPSC-based studies. We posit that reducing the clinical heterogeneity of hiPSC-based studies, by selecting subjects with common clinical manifestations or rare genetic variants, will help our ability to draw meaningful insights from the necessarily small patient cohorts that can be studied at this time. © 2014 Society of Biological Psychiatry.
Author supplied keywords
Cite
CITATION STYLE
Brennand, K. J., Landek-Salgado, M. A., & Sawa, A. (2014, June 15). Modeling heterogeneous patients with a clinical diagnosis of schizophrenia with induced pluripotent stem cells. Biological Psychiatry. Elsevier USA. https://doi.org/10.1016/j.biopsych.2013.10.025
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.